/
Contraceptive Update: CDC Medical Eligibility Criteria for Contraceptive Update: CDC Medical Eligibility Criteria for

Contraceptive Update: CDC Medical Eligibility Criteria for - PowerPoint Presentation

lindy-dunigan
lindy-dunigan . @lindy-dunigan
Follow
457 views
Uploaded On 2015-11-14

Contraceptive Update: CDC Medical Eligibility Criteria for - PPT Presentation

ARHP Learning Lab May 18 2011 Emily Godfrey MD MPH Expert Medical Advisory Committee Melanie Deal WHNP Student Health Services SF State University San Francisco CA David Grimes MD University of North Carolina School of Medicine ID: 192939

medical risk surgery cdc risk medical cdc surgery women www methods health contraceptive criteria postpartum http method hormonal gov

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Contraceptive Update: CDC Medical Eligib..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Contraceptive Update: CDC Medical Eligibility Criteria for Women With Certain Characteristics and Medical Conditions

ARHP Learning Lab

May 18, 2011

Emily Godfrey, MD, MPHSlide2

Expert Medical Advisory Committee

Melanie Deal, WHNP

Student Health Services, SF State University

San Francisco, CADavid Grimes, MD University of North Carolina School of MedicineChapel Hill, North Carolina

David Turok, MD

University of Utah, Dept. of Ob/Gyn

Salt

Lake City, UT

Susan Wysocki, WHNP-BC, FAANP

National Association of NPs in Women’s Health

Washington, DCSlide3

Learning Objectives

List the 4 levels in the numeric scheme described in the US

Medical Eligibility Criteria for Contraceptive Use, 2010Explain the application of the numeric scheme to prescriptive practices for women with co-morbid conditionsDescribe the risks and benefits of the different contraceptive methods against the risks of pregnancy in women with health-related concernsSlide4

Unplanned pregnancy – U.S. Unintended Pregnancy

Intended

Unintended (49%)

6.4 million pregnancies

51%

7%

20%

22%

Fetal Loss

Abortion

Birth

Finer LB, et al.

Persp Sex Reprod Health

. 2006

.

1.2 million

1.4 millionSlide5

Goals to Address Unintended Pregnancy

Healthy People 2020

Increase proportion of pregnancies that are intended

51%  56%Reduce proportion of females experiencing pregnancy despite reversible contraception use12.4%  9.9%CDC Winnable BattlesPublic health priorities with large-scale impact on health and with known, effective strategies to intervene To identify optimal strategies and to rally resources and partnerships to accelerate a measurable impact on health

Prevention of teen pregnancy is one of the 6 winnable battles

http://healthypeople.gov/2020/

http://www.cdc.gov/winnablebattles/teenpregnancy/index.htmlSlide6

Typical Effectiveness of Contraception

Adapted from: WHO. Family Planning: A Global Handbook

Long acting reversible contraceptives (LARCs)

Tier 1

Tier 2

Tier 4

Tier 3Slide7

Contraception Use

Mosher, W et al. 2010.Slide8

Improving Contraception Access

Improve access to and use of the most effective contraceptives

Address barriers to use of Long Acting Reversible Contraceptives (LARC)

Educate ProvidersEnsure dissemination of US MECRecommend that young women and nulliparous may be eligible to use LARC methodsIncrease interest and acceptance through education and social marketingAddress cost barriers to ensure publically funded services include LARC

http://www.cdc.gov/winnablebattles/teenpregnancy/index.htmlSlide9

US Medical Eligibility Criteria for Contraceptive Use

CDC published criteria in June ‘10

Based on the 4

th edition of the World Health Organization guidelines from ‘09Adapted for US women by panel of experts and CDCRecommendations for the use of specific contraceptives by women who have particular characteristics/medical conditions

http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/USMEC.htmSlide10

WHOCDC US MEC

Existing WHO guidance

Breastfeeding and hormonal methods

Valvular heart disease and IUDsPostpartum IUD insertionOvarian cancer and IUDsFibroids and IUDsDVT/PE and hormonal methods and IUDsSlide11

WHOCDC US MEC

New medical conditions

Rheumatoid arthritis

Endometrial hyperplasiaInflammatory bowel diseaseBariatric surgerySolid organ transplantationPeripartum cardiomyopathySlide12

US Medical Eligibility Criteria for Contraceptive UseSlide13

US Medical Eligibility Criteria: Organization

Criteria are organized according to:

Contraceptive method

Patient characteristics (age, smoking status, etc.)

Preexisting conditions (hypertension, epilepsy, etc.)

Criteria

use a numeric scheme to provide the recommendations for contraceptives being used for contraceptive purposes only,

not

for

treatment

of medical conditions

http://www.cdc.gov/mmwr/pdf/rr/rr5904.pdf

Slide14

1

No restriction for the use of the contraceptive method for a woman with that

medical condition

2

Advantages of using the method

generally outweigh the theoretical or proven

risks

3

Theoretical or proven risks of the method usually outweigh the advantages – or that there are no other methods that are available

or acceptable to the women with that medical condition4

Unacceptable health risk if the contraceptive method is used by a woman with that medical conditionUS Medical Eligibility Criteria: Categories

http://www.cdc.gov/mmwr/pdf/rr/rr5904.pdf Slide15
Slide16

Conditions Associated w/

Risk for Adverse Heath Events as a Result of Unintended Pregnancy

Breast

cancer

Malignant liver tumors (

hepatoma

) and

hepatocellular

carcinoma of the liver

Complicated

valvular

heart disease

Peripartum cardiomyopathyDiabetes: insulin dependent; with nephropathy/retinopathy/neuropathy or other vascular disease; or of >20 years’ durationSchistosomiasis with fibrosis of the liver

Endometrial or ovarian cancerSevere (decompensated) cirrhosisEpilepsy

Sickle cell disease

Hypertension

(systolic > 160 mm Hg or diastolic > 100 mm Hg)

Solid organ transplantation within the past 2 years

History of bariatric surgery within past 2 years

Stroke

HIV/AIDSSystemic lupus erythematosusIschemic heart disease

Thrombogenic mutationsMalignant gestational trophoblastic disease

Tuberculosis

http://www.cdc.gov/mmwr/pdf/rr/rr5904.pdf US Medical Eligibility Criteria: ↑ Risk for Adverse Health EventsShould consider long-acting, highly-effective contraception for these patientsSlide17

Pregnancy-Related Mortality

Increase in pregnancy-related mortality, 1998-2005

De-identified death certificates of women who died during or within 1 year of pregnancy

Matched birth or fetal death certificatesPregnancy-related mortality 14.5 per 100,000 live births

African American, 3-4 times greater risk

Decreased deaths due to hemorrhage and hypertensive disorders

Increased deaths due to medical conditions, especially CVD

Berg, CJ et al.

Obstet Gynecol

. 2010;116:1302-1309.Slide18

Case Presentation 1

Which hormonal methods are safe for her to use?

Combined hormonal methods only

Progestin-only methods onlyAny hormonal method

30-year-old

PPD #2

Ready to be discharged from hospital & desires contraception

Plans to breastfeedSlide19

BreastfeedingSlide20

Case Presentation 1

Which hormonal methods are safe for her to use?

Combined hormonal methods only

Progestin-only methods onlyAny hormonal method

30-year-old

PPD #2

Ready to be discharged from hospital & desires contraception

Plans to breastfeedSlide21

Case Presentation 2

Is this method safe for her?

Yes

No

25-year-old

Has

Crohn’s

disease

Desires long-term reversible contraception

Thinking about

levonorgestrel-releasing IUDSlide22

Inflammatory Bowel DiseaseSlide23

Case Presentation 2

Is this method safe for her?

Yes (Category 1)

No

25-year-old

Has

Crohn’s

disease

Desires long-term reversible contraception

Thinking about

levonorgestrel-releasing IUDSlide24

Case Presentation 3

What do you need to know before deciding whether to recommend this method?

How much weight has she lost?

What type of surgery did she have?What pill formulation did she use previously?

30-year-old

History of bariatric surgery 6 months ago

Was using COCs before surgery & wants to restartSlide25

Bariatric surgery

Most effective weight loss treatment for morbid obesity

From 1998 to 2005, incidence increased 800%

Women account for 83% of procedures among reproductive age (ages 18-45)Slide26

Types of Bariatric surgery

Restrictive procedures:

Decrease storage capacity of stomach

Ex: vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomyMalabsorptive procedures:Decrease absorption of nutrients and calories by shortening functional length of small intestineEx: Roux-en-Y gastric bypass (most common in US), biliopancreatic diversionSlide27

Bariatric Surgery

Consensus: Pregnancy should be avoided for 12-24 months after surgery

Paulen, ME et al.

Contraception

82 (2010) 86-94.Slide28

History of Bariatric SurgerySlide29

Case Presentation 3

What do you need to know before deciding whether to recommend this method?

How much weight has she lost?

What type of surgery did she have? What pill formulation did she use previously?

30-year-old

History of bariatric surgery 6 months ago

Was using COCs before surgery & wants to restartSlide30

Next Steps

Work with partners:

dissemination

implementation Keeping guidance up to dateSlide31

Updated Guidance from WHOSeptember 2010Slide32

What increased risk is posed by use of Combined Hormonal Contraceptives?

No data specifically delineates risk of CHC use during the postpartum

Baseline risk of VTE in non-pregnant, non-postpartum women:

2.4-10/10,000 WYCHC use increases risk:3-7 foldRisk most pronounced in the first year of useSlide33

Previous WHO MEC recommendation

CHCs in postpartum women

< 21 days postpartum 3

≥ 21 days postpartum 1Slide34

CHCs for women during the postpartum period

Condition

Recommendation

Clarification

Postpartum

a.

< 21 days

Without other risk factors for VTE

3

With other risk factors for VTE

3/4The category should be assessed according to the number, severity, and combination of VTE risk factors present.b. > 21 days to 42 days

Without other risk factors for VTE2With other risk factors for VTE2/3The category

should be assessed according to the number, severity, and combination of VTE risk factors present.c. > 42 days1Slide35

US MEC-Postpartum period

New evidence

Updated recommendations from WHO

CDC held consultation in Jan 2011Substantial increased risk in early weeks postpartum with no benefit Multiple risk factorsAccess issuesSafety of other contraceptive methods Will be published as MMWRSlide36

Next Steps

Work with partners:

dissemination

implementation Keeping guidance up to dateResearch gapsUS adaptation of WHO Selected Practice Recommendations for Contraceptive UseSlide37

Resources

US MEC published in CDC’s Morbidity and Mortality Weekly Report (MMWR):

http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s_cid=rr5904a1_w

CDC evidence-based family planning guidance documents:http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/USMEC.htmWHO evidence-based family planning guidance documents:http://www.who.int/reproductivehealth/publications/family_planning/en/index.html Slide38

Additional Resources

Association of Reproductive Health Professionals (ARHP)

www.arhp.org

National Association of Nurse Practitioners in Women’s Health (NPWH)www.npwh.org